arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

LeonaBio, Inc.

LONA
$4.34 ▼ -0.40 (-8.44%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
8 Visible periods
19 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, LeonaBio, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $18.6M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -290.7% ↘
FCF / Share $-10.69 ↗
Trailing P/E —
Price / Book 1.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

8-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-105.61M
↓ -8.9% —
FCF / Share Free cash flow per share
$-10.69
↑ +57.7% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -290.7% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.43x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↓
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 30 quarters